.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Accenture
Johnson and Johnson
Julphar
Fish and Richardson
Citi
Mallinckrodt
Novartis
Chinese Patent Office

Generated: November 22, 2017

DrugPatentWatch Database Preview

ZIOPTAN Drug Profile

« Back to Dashboard

What is the patent landscape for Zioptan, and what generic Zioptan alternatives are available?

Zioptan is a drug marketed by Oak Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in thirteen countries and eight supplementary protection certificates in eight countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tafluprost profile page.

Pharmacology for ZIOPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc
ZIOPTAN
tafluprost
SOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Oak Pharms Inc
ZIOPTAN
tafluprost
SOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ZIOPTAN

Drugname Dosage Strength RLD Submissiondate
tafluprostOphthalmic Solution0.0015%Zioptan2/10/2016

Non-Orange Book Patents for Tradename: ZIOPTAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,920 Difluoroprostaglandin derivatives and their use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZIOPTAN

Country Document Number Estimated Expiration
Japan2004002462► Subscribe
Japan3994074► Subscribe
Netherlands300407► Subscribe
Luxembourg91943► Subscribe
China1108289► Subscribe
Norway317060► Subscribe
Austria225770► Subscribe
Taiwan536534► Subscribe
Spain2187719► Subscribe
Norway976085► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZIOPTAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9Finland► Subscribe
0850926/01Switzerland► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
0407Netherlands► Subscribe300407, 20171222, EXPIRES: 20221221
C/GB09/005United Kingdom► SubscribePRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
C013/2011Ireland► SubscribeSPC013/2011: 20110808, EXPIRES: 20221221
2008 00041Denmark► Subscribe
943Luxembourg► Subscribe91943, EXPIRES: 20221222
C0020France► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Johnson and Johnson
Fish and Richardson
Express Scripts
Medtronic
Boehringer Ingelheim
Chinese Patent Office
Moodys
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot